Phosphoramidate-based peptidomimetic inhibitors of membrane type-1 matrix metalloproteinase

4Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Membrane-type I matrix metalloproteinases (MT1-MMP) is an enzyme critical to the remodeling and homeostasis of extracellular matrix, and when over expressed it contributes to metastasis and cancer cell progression. Because of its role and implication as a biomarker that is upregulated in various cancers, MT1-MMP has become an attractive target for drug discovery. A small pilot library of peptidomimetics containing a phosphoramidate core as a zinc-binding group was synthesized and tested for inhibitory potency against MT1-MMP. From this library, a novel two residue peptidomimetic scaffold was identified that confers potency against MT1-MMP at submicromolar concentrations. The results of this study confirm that for this scaffold, valine is favored as a P1 residue and leucine in the P1′ position. Furthermore, steric tolerance was observed for the N-terminus, thus implicating that a second-generation library could be constructed to extend the scaffold to P2 without concomitant loss of affinity within the MT1-MMP catalytic domain.

Author supplied keywords

Cite

CITATION STYLE

APA

Mendes, D. E., Wong-On-Wing, A., & Berkman, C. E. (2016). Phosphoramidate-based peptidomimetic inhibitors of membrane type-1 matrix metalloproteinase. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(1), 167–171. https://doi.org/10.3109/14756366.2015.1010528

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free